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Abstract 
We generated mice with a selective loss of GABAB receptors in orexin neurons.  Orexin neurons in 
these GABAB1-/-(orexin) mice showed reduced responsiveness to GABAA receptor agonists due to a 
compensatory increase in GABAA receptor-mediated inhibition. This increased GABAA 
receptor-mediated inhibition of orexin neurons is due to orexin-1 receptor-mediated activation of 
local GABAergic interneurons.  Surprisingly, orexin neurons were also less responsive to glutamate, 
apparently because the augmented GABAA receptor-mediated inhibition increases the membrane 
conductance and shunts excitatory currents.  These observations indicate that absence of GABAB 
receptors decreases the sensitivity of orexin neurons to both excitatory and inhibitory inputs.  
GABAB1-/-(orexin) mice exhibited severe fragmentation of sleep/wake states during both the light and 
dark periods without affecting total sleep time or inducing cataplexy, indicating that GABAB receptors 
are crucial regulators of orexin neurons and that “fine tuning” of orexin neurons by inhibitory and 
excitatory inputs is important for the stability of sleep/waking states. 
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Orexin A and orexin B, also known as hypocretin-1 and hypocretin-2, are critical regulators of 
sleep/wakefulness states1.  Orexin neurons are localized exclusively in the lateral hypothalamic area 
(LHA) and send excitatory projections to the waking-active monoaminergic neurons in the 
hypothalamus and brainstem regions1.  The importance of orexins in the maintenance of 
consolidated sleep/wakefulness states is demonstrated by the fact that the sleep disorder 
narcolepsy is caused by orexin deficiency in human and animals2-5.  Investigations of the efferent 
and afferent systems of orexin neurons and phenotypic characterization of genetically-modified mice 
have suggested additional functions for the orexins in the coordination of emotions, energy 
homeostasis, reward systems, drug addiction, and arousal1.  
The regulatory mechanisms of orexin neurons are important for understanding the 
physiological basis of sleep/wake control.  In vitro studies showed that the activity of orexin neurons 
is influenced by several neuropeptides and neurotransmitters1.  Recent studies showed that orexin 
neurons receive innervation from several brain regions, including the limbic system (amygdala, bed 
nucleus of the stria terminalis, and septal regions), preoptic area, and monoaminergic neurons1,6.  
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Orexin neurons also receive glutamatergic and GABAergic innervation from local interneurons1,7. In 
vitro electrophysiological studies showed that both GABAA and GABAB agonists inhibit the activity of 
orexin neurons7-9, but the physiological relevance of such regulation is unknown.  
GABAB receptors (GABABRs) are heterodimers composed of GABAB1 and GABAB2 
subunits, both of which are required for normal receptor function10,11.  GABAB receptors are coupled 
to G-proteins and modulate synaptic transmission by activating postsynaptic inwardly rectifying Kir3 
K+ channels (GIRK channels) and by controlling neurotransmitter release through coupling to Ca2+ 
channels12,13. Dysfunction of GABAB-mediated synaptic transmission in the central nervous system 
occurs in several neurological disorders13-15.  Among sleep disorders, the partial GABABR agonist 
gamma-hydroxybutyrate (GHB)16 is used to treat both the excessive sleepiness and cataplexy 
symptoms of human narcolepsy.  GABABR activation inhibits presynaptic release of both glutamate 
and GABA onto orexin neurons9 and both pre- and postsynaptic GABABRs modulate the activity of 
orexin neurons9.  In the present study, we engineered mice with a selective deletion of the GABAB1 
gene in orexin neurons (orexin neuron-restricted knockout mice; GABAB1-/-(orexin) mice) to study the 
consequences of the absence of GABABRs on orexin neuron function at the cellular and behavioral 
levels.  
Results 
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Mice Selectively Lacking Functional GABAB Receptors in Orexin Neurons 
The GABAB1 subunit is essential for the assembly of functional GABAB receptors and mice lacking 
the GABAB1 subunit show a complete absence of GABAB responses17.  To obtain mice with a deletion 
of the GABAB1 subunit gene restricted to orexin-producing neurons (GABAB1-/-(orexin) mice), orexin/Cre 
transgenic mice (see supplementary information) were mated with homozygous floxed GABAB1 mice 
possessing exon 7 and 8 of the GABAB1 allele flanked by lox-P sites18.  Double immunofluorescence 
studies in wild-type control mice showed that many neurons in the LHA had GABAB1-ir in their soma 
and dendrites (Figure 1).  Among these, many neurons in the LHA were positive for both orexin-ir 
and GABAB1-ir (Figure 1).  In contrast, neurons positive for both GABAB1-ir and orexin-ir were rarely 
detectable in the brain of GABAB1-/-(orexin) mice, although there were many GABAB1-ir-positive neurons 
in the LHA that were negative for orexin (Figure 1).  We found that less than 10% of orexin neurons in 
GABAB1-/-(orexin) mice were double-labelled for orexin and GABAB1-ir.  This may be due to incomplete 
penetrance of Cre expression in orexin/Cre transgenic mice and/or incomplete deletion of loxP sites 
in GABAB1-/-(orexin) mice.  These observations indicate that in GABAB1-/-(orexin) mice, more than 90% of 
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orexin neurons lack expression of GABAB receptors.  Gross anatomical and histological studies 
failed to detect any structural abnormalities in the brain of GABAB1-/-(orexin) mice.  Specifically, the 
number of orexin neurons in the LHA remained normal;  the number of immunoreactive cells (located 
from 0.76 mm to 2.52 mm posterior to bregma) were 3420±124 and 3560±108 for control littermates 
and GABAB1-/-(orexin) mice, respectively (n=5). 
GABAB1-/-(orexin) mice showed normal development of body weight; body weights at 22 weeks 
of age were 35.9±2.9, 34.9±2.5, and 34.8±1.8 g for GABAB1flox/+, orexin/Cre Tg mice (n=9), 
GABAB1flox/flox (orexin/Cre negative) mice (n=6), and GABAB1-/-(orexin) mice (n=6), respectively (p=0.35, 
ANOVA with Bonferroni correction).  Expression levels of hypothalamic neuropeptides, including 
orexin, neuropeptide Y, proopiomelanocortin, and melanin concentrating hormone, did not differ 
between GABAB1-/-(orexin) and control mice, as determined by quantitative RT-PCR using Taqman 
probes or immunohistochemical analysis (data not shown).  In contrast to conventional GABAB1 KO 
mice that exhibit contextual hyperactivity,17 locomotor activity of GABAB1-/-(orexin) mice across the 24 hr 
period was not altered (data not shown). 
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Electrophysiological Characteristics of Orexin Neurons Lacking GABAB Receptors 
The electrophysiological properties of orexin neurons were examined in GABAB1-/-(orexin) mice by 
patch-clamp recordings using brain slice preparations (Figure 2).  Bath application of GABA (0.6 mM) 
or muscimol (30 μM) produced hyperpolarization of orexin neurons in both control (GABAB1flox/+, 
orexin/Cre Tg or GABAB1flox/flox, orexin/Cre negative) and GABAB1-/-(orexin) mice (Figure 2a, b).  These 
GABA- and muscimol-induced effects rapidly reversed upon removal of these reagents from the 
external solution (Figure 2a, b).  To specifically examine GABAB receptor-mediated effects on 
neuronal activity, we applied the GABAB agonist baclofen.  Bath application of baclofen (100 μM) 
hyperpolarized all orexin neurons tested in control slices (n=6) (Figure 2a).  As expected from the 
histological data in Figure 1, baclofen failed to induce hyperpolarization in 10 out of 12 orexin 
neurons tested in slices from six GABAB1-/-(orexin) mice (Figure 2b).  Application of 5-hydroxytryptamine 
(5-HT) induced strong hyperpolarization of orexin neurons regardless of genotype, suggesting that 
downstream signaling systems of Gi/o-coupled receptors, including the activation of Kir3 channels, 
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remain intact in GABAB1-/-(orexin) mice (Figure 2a, b).  
In current-clamp mode, orexin neurons lacking GABAB receptors showed a resting 
membrane potential and firing frequency similar to that of orexin neurons in control littermates 
(GABAB1-/-(orexin): -59.2±5.8 mV, 5.1±2.6 Hz, n=12; control: -55.0±2.9 mV, 4.0±0.7 Hz, n=12), 
indicating that GABAB receptor-deficient orexin neurons have a basal activity comparable to that of 
control neurons, despite the absence of a major inhibitory receptor.  However, the frequency of fast 
spontaneous inhibitory postsynaptic currents (sIPSCs) of orexin neurons in GABAB1-/-(orexin) slices 
was significantly increased compared to that in slices from control littermates (GABAB1-/-(orexin): 
2.65±0.32 Hz, n=9; control: 1.59±0.12 Hz, n=13; p=0.011) (Figure 3a, b).  Bath application of 
baclofen (100 μM) decreased the frequency of sIPSCs to 3.4% and 23% of control values (in the 
absence of baclofen) in control littermates and GABAB1-/-(orexin) mice, respectively (Figure 3a, b).  This 
suggests that sIPSCs on orexin neurons are elicited by GABA release from GABAergic terminals 
having presynaptic GABAB receptors (Figure 3a, b).  Next, we examined the effects of the GABAA 
and GABAB receptor antagonists bicuculline (BIC) and CGP54626, respectively, on the activity of 
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orexin neurons.  Consistent with our previous study9, orexin neurons in wild-type control slices did 
not respond to applications of the antagonists BIC (25 μM) or CGP54626 (12 μM) (Figure 3c and 
data not shown).  In contrast, orexin neurons in slices from GABAB1-/-(orexin) mice responded with 
depolarization to BIC application (n=4) (Figure 3c).  These findings indicate that GABAA receptors 
are tonically activated in orexin neurons of GABAB1-/-(orexin) mice but not in wild-type mice.  The 
spontaneous excitatory postsynaptic currents (sEPSCs) of orexin neurons from GABAB1-/-(orexin) and 
control littermate mice were comparable (GABAB1-/-(orexin): 5.1±0.73 Hz, n=4; control: 5.8±1.2 Hz, n=3; 
p= 0.74).  These results indicate that the inhibitory GABAA input to orexin neurons is increased, while 
excitatory glutamatergic input to orexin neurons remains unchanged in GABAB1-/-(orexin) mice.  This 
mechanism might prevent offset of the resting membrane potential and firing frequency of orexin 
neurons in GABAB1-/-(orexin) mice.   
To further analyze the mechanisms that increase sIPSC frequency in orexin neurons lacking 
GABAB receptors, we recorded miniature IPSCs (mIPSCs).  mIPSCs were isolated by adding 
tetrodotoxin (TTX) (1 μM) to the sIPSC recording solution.  We found that the mean frequency and 
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peak currents of mIPSCs in orexin neurons of GABAB1-/-(orexin) mice were comparable to that of control 
mice (GABAB1-/-(orexin): 1.1±0.29 Hz, 94.5±21.0 pA, n=5; control: 0.99±0.26 Hz, 104.5±11.2 pA, n=6; 
p>0.05 by Student’s t test).  These results suggest that the increase of sIPSCs in GABAB1-deleted 
orexin neurons is due to an increase in the local GABAergic tone, rather than to an increase in 
GABAA receptors or the number of GABAergic synapses. Due to increase in GABAA input, the 
membrane resistance of orexin neurons in GABAB1-/-(orexin) mice was significantly decreased (control: 
466 ± 29 MΩ, n=25; GABAB1-/-(orexin): 364 ± 27 MΩ, n=12; p= 0.017, Student’s t test) (Figure 3e).   
Since the genetic deletion of the GABAB1 gene is restricted to orexin neurons (Figure 1), the 
increase in sIPSP frequency in orexin neurons must be attributable to a dysregulation of these 
neurons. Interestingly, we found that application of orexin A (1 μM) increased the frequency of 
sIPSCs in wild-type orexin neurons (baseline: 1.6 ± 0.25 Hz; orexin A: 2.7 ± 0.33 Hz; washout: 1.5 ± 
0.32 Hz; n= 5; p <0.05 by one-way ANOVA), suggesting that orexin-induced activation of local 
GABAergic neurons is involved in the increase of inhibitory input to orexin neurons in GABAB1-/-(orexin) 
mice.  We hypothesized that the activity of local GABAergic neurons expressing the orexin receptor 
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is increased in GABAB1-/-(orexin) mice due to increased orexin release onto these interneurons. To 
evaluate this possibility, the orexin receptor antagonist SB334867 was used to block the orexin 
receptor-1 (OX1R).  Preincubation with SB334867 (5 μM) reduced the frequency of sIPSCs in orexin 
neurons of GABAB1-/-(orexin) mice (basal: 2.7 ± 0.43 Hz, n = 6; SB334867: 1.1 ± 0.30 Hz, n = 7; p= 
0.012 by Student t test), but had no effect in control littermate mice  (1.1 ± 0.36 Hz, n = 4  vs 1.0 ± 
0.13 Hz, n = 9, p= 0.769 by Student t test) (Fig, 3d). These results indicate that orexin activates local 
GABAergic neurons via the OX1R resulting in an increase of the GABAergic synaptic input onto 
orexin neurons, and that activity of these local circuits is increased in GABAB1-/-(orexin) mice. 
 
Decreased Responsiveness of Orexin Neurons Lacking GABAB Receptors to Excitatory and 
Inhibitory Inputs 
Although the basal membrane potential and firing frequency of orexin neurons in GABAB1-/-(orexin) mice 
were comparable to that of wild-type mice due to the compensatory increase in GABAergic input, the 
absence of GABAB receptors caused abnormalities in these cells.  We found that the effect of the 
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GABAA agonist muscimol on orexin neuron activity was markedly attenuated in GABAB1-/-(orexin) mice 
(Figure 4a, b).  In current clamp mode, the threshold for hyperpolarization of orexin neurons by 
muscimol was 1.2 μM and 6 μM in littermate control slices and GABAB1-/-(orexin) slices, respectively.  
These findings indicate that the responses of orexin neurons to the GABAA agonist muscimol are 
decreased in slices from GABAB1-/-(orexin) mice.  Tonic activation of GABAA receptors might explain 
why the exogenous application of the GABAA agonist muscimol had a less potent effect on orexin 
neurons in GABAB1-/-(orexin) mice since, under basal conditions, GABAA receptors in these neurons are 
already tonically activated by GABA (Figure 3c).  
Next, we examined the effect of an excitatory neurotransmitter, glutamate, on the activity of 
orexin neurons.  The effects of glutamate were markedly attenuated in GABAB1-/-(orexin) mice (Figure 
4c, d).  These findings suggest a decrease in the membrane resistance of orexin neurons in 
GABAB1-/-(orexin) mice (Figure 3e) due to excess GABAAR activation by increased local GABAergic 
neuron activity which results in decreased sensitivity to both excitatory and inhibitory inputs. This 
decreased sensitivity might be due to the increase in membrane conductance (Figure 3e), which 
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caused shunting of excitatory input, although the resting membrane potential was comparable to 
control. 
 
GABAB1-/-(orexin) Mice Exhibit Severe Behavioral State Disruption 
To examine the in vivo consequences of dysregulation of orexin neurons resulting from the absence 
of GABAB receptors, behavioral state patterns of GABAB1-/-(orexin) mice and control littermate mice 
were studied by simultaneous EEG/EMG recordings5,19,20.  Typical hypnograms (graphic 
representations of sleep-waking states over time) of GABAB1-/-(orexin) mice and control littermates 
during the 24 hr dark and light periods are shown in Figure 5a and 5b.  Although the overall amounts 
of wakefulness, non-REM, and REM sleep were similar between the two strains (Figure 5c), 
GABAB1-/-(orexin) mice displayed severe fragmentation of sleep/wakefulness states indicated by 
decreased awake, non-REM, and REM sleep episode durations and reduced REM latency (Figure 
5d and Table 1).  The fragmentation of sleep/wakefulness states in GABAB1-/-(orexin) mice was more 
severe than that previously described in orexin-knockout mice or even in orexin/ataxin-3 transgenic 
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mice in which orexin neurons are specifically ablated5,20.  However, neither the direct transitions from 
an awake state to REM sleep nor the cataplexy-like behavioral arrests that are occasionally 
observed in both orexin-deficient mice and orexin neuron-ablated mice were observed in 
GABAB1-/-(orexin) mice5,20.  Interestingly, in contrast to the findings in orexin-deficient mice in which 
fragmentation is only observed during the dark period,5,20 fragmentation of behavioral states in 
GABAB1-/-(orexin) mice occurred during both the light and the dark periods (Figure 5 and Table 1).  
Although the total sleep time of GABAB1-/-(orexin) mice tended to increase when compared to control 
mice, this difference was not statistically significant (Figure 5 and Table 1).  These changes along 
with a decrease in REM sleep latency indicate increased pressure for entry into REM sleep in 
GABAB1-/-(orexin mice. 
Discussion 
Orexin neurons are indispensable components of the regulatory mechanism that controls 
sleep/wake states.  We have previously studied the regulatory mechanisms of orexin neurons in 
vitro7,8,21-24.  However, the physiological relevance of the regulatory mechanisms or inputs affecting 
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the activity of orexin neurons remains unknown.  In this study, we addressed the importance of 
GABA, the major inhibitory neurotransmitter in the mammalian central nervous system, because the 
proper functioning of neurons is dependent upon the regulation of neural activity by GABA-releasing 
neurons.  Moreover, GABA has been implicated in the regulation of sleep.  For instance, GABAA 
receptor activation is well-known to induce sleep-promoting responses25.  Administration of the 
GABAB agonist baclofen (25 mg) before sleep in a clinical study also significantly prolonged total 
sleep time and reduced the time spent awake after sleep onset26.  The GABAB antagonist CGP 
35348 increased the duration of both non-REM and REM sleep in aged rats compared to those in 
saline-injected controls when injected during the night27 and decreased non-REM sleep while 
increasing the duration of waking and REM sleep when injected during the day28.  These results 
suggest an important role for GABAB receptors in the regulation of sleep/wakefulness states.  
The present experiments showed that typical GABAB responses are almost completely 
eliminated in orexin neurons from GABAB1-/-(orexin) mice (Figure 2).  GABAB agonist-induced 
postsynaptic effects were also eliminated and the sensitivity of orexin neurons to both GABAA 
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receptor agonists and glutamate was decreased in GABAB1-/-(orexin) mice (Figure 4).  As shown in 
Figure 3, we also found that inhibitory synaptic inputs to orexin neurons are increased in 
GABAB1-/-(orexin) mice.  However, in the presence of TTX, mIPSC frequencies are comparable between 
GABAB1-/-(orexin) and control orexin neurons (data not shown).  These observations suggest that 
spontaneous GABA release onto orexin neurons was not increased, but that activity-dependent 
inhibitory signals from local GABAergic neurons onto orexin neurons were increased in slice 
preparations from GABAB1-/-(orexin) mice.   
Because deletion of the GABABR was confined to orexin neurons (Figure 1), the increase 
in GABAergic influence must be attributable to the abnormality of the orexin neurons. We suggest 
that orexin neurons innervate local GABAergic neurons that, in turn, send inhibitory projections onto 
the orexin neurons (Figure 6).  In the parental GABAB1 floxed line, exons 7 and 8 of GABAB1 gene are 
flanked by lox-P sites18. Therefore, both the GABAB1a and GABAB1b subtypes are deficient in the 
orexin neurons of the GABAB1-/-(orexin) mice, which therefore lack functional GABAB receptors 
altogether.  Presumably, in the GABAB1-/-(orexin) mice, orexin release is increased due to the lack of 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
07
.1
19
5.
1 
: P
os
te
d 
29
 S
ep
 2
00
7
Matsuki et al., page 18 
functional GABAB receptors in the nerve terminal or the somatodendritic compartment of orexin 
neurons, leading to excessive activation of local GABAergic neurons. Consistent with this hypothesis, 
preincubation of GABAB1-/-(orexin) slices with the OX1R antagonist reduced the sIPSC frequency to a 
level similar to that found in control slices (Figure 3d).  
These alterations in the synaptic input of orexin neurons due to a lack of functional GABAB 
receptors result in severe sleep/waking fragmentation in GABAB1-/-(orexin) mice during both the light 
and dark periods (Figure 5 and Table 1), indicating that the GABAB receptor in orexin neurons is 
indispensable for proper regulation of sleep/wake states.  As to why GABAB1-/-(orexin) mice showed 
robust fragmentation of sleep/wake behavior in both the dark and light periods, we have previously 
hypothesized that orexin neurons are appropriately regulated to maintain proper vigilance states 
according to the animals’ environment1.  In GABAB1-/-(orexin) mice, the effects of both GABA and 
glutamate in orexin neurons were severely impaired. Therefore, orexin neurons in these mice are 
unlikely to be appropriately and tightly regulated (Figure 4).  
Orexin knockout mice and orexin neuron-deficient mice show behavioral instability and 
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sleep/wake fragmentation only during the dark (active) period5,20.  In contrast, transgenic mice with 
constitutive overexpression of orexin show a fragmented sleep/wake phenotype only during the light 
(rest) period.  The activity of orexin neurons is high during the dark period29; therefore, abnormality of 
orexin-/- mice during this period might be expected. On the other hand, since the activity of orexin 
neurons is low or quiescent during the light period, the sleep/wake abnormality of 
orexin-overexpressing mice becomes apparent during this period30.  However, GABAB1-/-(orexin) mice 
showed robust fragmentation of sleep/wake behavior during both the dark and light periods.  In the 
light (rest) period, orexin neurons might be inhibited by GABAergic influences from GABAergic 
neurons in the preoptic area1, which are likely important for stably silencing orexin neurons31,32.  In 
GABAB1-/-(orexin) mice, both GABAA- and GABAB-mediated inhibition of orexin neurons was severely 
impaired (Figures 2, 3, and 4).  These defects may explain why these mice showed fragmented sleep 
in the light period, because orexin neurons in GABAB1-/-(orexin) mice cannot be effectively inhibited by 
GABA.  On the other hand, during the dark (active) period, orexin neurons would be activated by 
various excitatory inputs including glutamatergic influences1.  In GABAB1-/-(orexin) mice, the effect of 
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glutamate on orexin neurons was also severely impaired (Figure 4); consequently, the activity of 
orexin neurons is not appropriately regulated to maintain wakefulness according to various inputs 
(Figure 6).  
In GABAB1-/-(orexin) mice, we did not observe the cataplexy-like behavioral arrests or the direct 
transitions from wakefulness to REM sleep that are occasionally seen in orexin-deficient animals. 
This result is consistent with the observation that mice overexpressing orexin do not show cataplexy, 
although these mice show fragmentation of sleep/wakefulness states during the light period30. 
Together, these results suggest that fine tuning of orexinergic tone may not be necessary for 
inhibition of cataplexy and direct transition from wakefulness to REM sleep.  On the other hand, the 
present study showed that fine tuning of orexin neurons is crucial for stability of sleep/wakefulness 
states and maintenance of normal sleep/wake architecture (Fig. 5d).  
This study demonstrated the importance of GABAB activity in a defined neuronal circuit and the 
importance of orexin neuron GABABRs for maintenance of wakefulness and sleep state 
consolidation.  The phenotype of GABAB1-/-(orexin) mice is characterized by impaired ability to maintain 
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any behavioral state, which is one of the primary symptoms of human narcolepsy. Therefore, 
GABAB1-/-(orexin) mice may be a useful model in which to study narcolepsy without cataplexy.  Since the 
partial GABAB agonist GHB is used clinically to extend both sleep bouts and subsequent 
wakefulness, thereby allowing narcoleptic humans to engage in longer periods of purposeful activity 
during their waking hours, GABAB1-/-(orexin) mice may also be a useful model in which to study the 
therapeutic action of GHB.  Impaired ability to maintain wakefulness and consolidate sleep is also 
one of the hallmarks of sleep in the elderly.  Given the widespread use of hypnotic medications that 
target GABAergic signalling, it will be interesting to determine whether age-related defects in 
GABAergic control of orexin neurons occur.  Lastly, the orexin neurons have been proposed to be a 
crucial component of a “flip-flop” switch controlling sleep and wakefulness25.  The orexin system is 
hypothesized to be the stabilizer of the flip-flop switch1. The phenotype of the GABAB1-/-(orexin) mice 
suggests that fine regulation of orexin neuronal activity is necessary for proper function of the flip-flop 
switch.  
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Methods 
Animal Usage 
All experimental procedures involving animals were approved by the Animal Experiment and Use 
Committee of University of Tsukuba and were in accordance with NIH guidelines. 
Generation of Orexin/Cre Transgenic Mice 
The transgenic construct was made by substituting the nlacZ gene (SalI-BamHI fragment) of the 
orexin/nlacZ transgenic construct33 with the Cre-recombinase cDNA and an internal ribosome entry 
site with the eGFP (IRES-eGFP) gene (see supplementary information).  The transgene was 
linearized and microinjected into pronuclei of fertilized mouse eggs from the F1 of C57BL/6 x DBA1; 
BDF1.  Founder animals were bred with C57BL/6 mice to produce a stable orexin/Cre line.  
Genotyping of orexin/Cre transgenic mice was performed by PCR of tail DNA.  Human prepro-orexin 
promoter sequences, Cre recombinase, and eGFP coding sequences were amplified with PCR 
primer sets: human prepro-orexin genomic fragment, sense: GCAGCGGCCATTCCTTGG, 
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anti-sense: AAGTCGACGGTGTCTGGCGCTCAGGGTG; Cre recombinase, sense: 
GGTTCGTTCACTCATGGAAAATAG, anti-sense: GGTATCTCTGACCAGAGTCATCCT; eGFP, 
sense: GAAGGGCATCGACTTCAAGG, anti-sense: ACGAACTCCAGCAGGACCAT. 
Breeding and Maintenance of Mouse Lines 
Orexin/Cre mice were mated with GABAB1flox/flox (BALB/cA) mice18 and a breeding colony for 
producing orexin/Cre, GABAB1flox/flox (GABAB1-/-(orexin); BALB/cA: C57BL/6: DBA1 mixed background) 
was maintained by mating GABAB1flox/flox with orexin/Cre, GABAB1flox/+ mice.  To detect Cre 
recombinase expression, we mated orexin/Cre Tg mice with 129-Gt(ROSA)26Sor(EGFP)/J reporter 
mice (Jackson Laboratories) (Supplementary fig. 1).  
We produced mice with selective deletion of the GABAB1 gene in orexin neurons by crossing 
GABAB1flox/flox and orexin/Cre Tg mice.  The genetic background of the mice used in this study was a 
mixture of BALB/c, C57BL/6, and DBA1 (75% : 21.875% : 3.125%).  These mice with either a 
C57BL/6 background or a C57BL/6 and DBA1 mixed background showed similar sleep/wakefulness 
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behavior, consistent with previous studies34,35.  The total daily duration of non-REM sleep did not 
significantly differ between strains, even though the BALB/c strain has been reported to exhibit a 
shorter period of time in non-REM sleep during the day than the night36.  These similarities suggest 
that differences in genetic background have minimal effects on the results of our study.  To further 
minimize the effect of genetic background, all experiments were performed with littermates as 
controls.  We found that wild type mice, orexin/Cre Tg mice, GABAB1flox/+, orexin/Cre Tg mice and 
GABAB1flox/flox (orexin/Cre-negative) mice all show the same phenotype regarding sleep/wakefulness 
states (data not shown).  In this study, GABAB1flox/flox, orexin/Cre Tg mice were used as GABAB1 
spatially-restricted KO mice, while GABAB1-/-(orexin) mice and their GABAB1flox/flox, orexin/Cre-negative 
littermates were used as controls unless otherwise stated.  
For electrophysiological analysis, GABAB1-/-(orexin) mice were mated with orexin/eGFP 
transgenic mice (C57BL/6 background) to prepare GABAB1-/-(orexin) mice with expression of eGFP as a 
marker of orexin neurons19.  
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Histological Analysis 
Mouse brains were fixed and prepared as previously described37.  Mice were anesthetized by 
intraperitoneal injection of sodium pentobarbital and perfused via the heart with phosphate-buffered 
saline (PBS), followed by 0.1 M phosphate buffer containing 4% paraformaldehyde.  The whole brain 
was postfixed for 2 hr in 4% paraformaldehyde in PBS.  Sections were washed with 0.3% Triton 
X-100 in PBS and incubated with 1% bovine serum albumin in PBS for 1 hr, and then incubated with 
primary antibodies in the same solution for 1 hr at room temperature.  Staining was performed with 
standard procedures using rabbit or guinea pig anti-orexin antisera37, mouse anti-Cre antibody 
(Nacalai), or guinea pig anti-GABAB1 antibody (Chemicon) and Alexa 488 or 594-conjugated 
secondary antibodies (Invitrogen). 
EEG/EMG Recording 
Male GABAB1-/-(orexin) mice (n=10) and their weight-matched male control littermates (GABAB1flox/+, 
orexin/Cre Tg mice, n=5; or GABAB1flox/flox (orexin/Cre-negative) mice, n=6) were implanted with 
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electrodes at 12 weeks of age to record simultaneous EEG/EMG, as described previously5.  Animals 
were allowed to recover and habituate for 2 weeks under a constant 12 hr light/dark cycle at 25°C 
with free access to food and water.  Continuous EEG/EMG traces were recorded with ad libitum 
feeding for the first 48 hr (baseline).  Traces were captured and digitized in 20 s epochs.  Each of two 
investigators, blinded to genotype, scored and categorized all epochs as wakefulness, REM sleep, 
or non-REM sleep according to standard criteria of rodent sleep.  REM latency was determined as 
the time between the onset of sleep and the first REM sleep period.  Inter-REM interval was 
calculated as the duration between successive REM sleep episodes.  Data were analyzed by 
ANOVA for repeated measurements to detect interactions between genotype and vigilance state 
parameters. 
Electrophysiological Studies 
Male and female GABAB1-/-(orexin) (GABAB1flox/flox, orexin/Cre Tg), control (GABAB1flox/+; orexin/Cre Tg or 
GABAB1flox/flox, orexin/Cre negative), and orexin/eGFP mice, 2-5 weeks old, were used for the 
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experiments.  The brain was cut coronally into 300-µm slices with a microtome (Leica) in 
Ringer-sucrose buffer bubbled with 95% O2/5% CO2 gas.  Slices containing the LHA were 
transferred to an incubation chamber filled with a physiological solution containing the following (in 
mM): 140 NaCl, 2 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES, and 10 glucose, pH 7.4, at room temperature 
(24-26ºC) for at least for 1 hr.  For electrophysiological recording, the slices were kept at a controlled 
temperature of 34ºC and were superfused with a physiological solution that was warmed by an in-line 
heater (Warner Instruments) to 34ºC.  A fluorescence microscope equipped with an infrared camera 
(Hamamatsu Photonics) for infrared differential interference contrast imaging and a charge-coupled 
device camera (Olympus Optical) was used for fluorescent imaging.  For whole cell patch-clamp 
recording, pipettes were filled with an internal solution, HEPES-buffered potassium chloride (KCl) or 
potassium methanesulfonate (KMeSO4) solution, as previously described9.  Pipette resistance was 
5-10 MΩ.  The series resistance during recording was 10-40 MΩ and was not compensated.  The 
liquid junction potential of the patch pipette solution and perfused HEPES solution was estimated to 
be 3.9 mV and was applied to the data.  The membrane patch was then ruptured by suction, and 
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membrane current and potential were monitored using an Axopatch 200B patch-clamp amplifier 
(Axon Instruments).  Data were recorded on a computer through a Digidata 1322A analog-to-digital 
converter using pClamp 10.0 software (Axon Instruments).  sEPSCs were recorded using KCl 
internal solution supplemented with the sodium channel blocker QX-314 (1 mM) to inhibit action 
potentials in the neuron, and bicuculline (BIC; 20 µM) and picrotoxin (PTX; 100 µM) were added to 
the physiological HEPES solution to block GABAA receptor-mediated neurotransmission.  sIPSCs 
were recorded using the same pipette solution but with addition of 
6-cyano-7nitroquinoxaline-2,3-dione (CNQX, 20 µM) and DL-2-amino-5-phosphono-pentanoic acid 
(AP-5, 50 µM) to the bath solution to block AMPA and NMDA receptor-mediated neurotransmission.  
mIPSCs were recorded in the presence of 1 µM TTX, 20 µM CNQX and 50 µM AP-5.  Frequencies 
and amplitudes of spontaneous and miniature synaptic events were measured using the Mini 
Analysis Program version 6.0 (Synaptosoft) from recordings before, during and after washout of the 
drug.  Only those events with amplitudes > 10 pA were used.  Electrophysiological traces were 
processed for presentation using Origin 7.5 (Origin Lab Corporation). 
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Drugs 
The drugs used were glutamate, GABA, muscimol, baclofen, BIC, PTX, CNQX, 5-HT, and AP5 
(Sigma), TTX (Wako), CGP54626 and SB334867 (Tocris), and CCK, orexin A and orexin B (Peptide 
Institute).  Drugs were dissolved in DMSO or the buffers suggested by the suppliers and were diluted 
with bath HEPES buffer. 
Statistical Analysis 
Data are presented as mean±SEM and were analyzed by one-way or repeated-measurements 
ANOVA followed by post hoc analysis of significance by Scheffé’s F test or Fisher’s Protected Least 
Significant Difference test using the GraphPad Prism version 4 software package (GraphPad 
Software). 
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Figure legends 
Figure 1. Selective Loss of GABAB Receptors in Orexin Neurons in GABAB1-/-(orexin) Mice.  
GABAB1-/-(orexin) (GABAB1flox/flox, orexin/Cre Tg) mice showed loss of GABAB1 receptor gene expression 
in orexin neurons.  Matched brain sections from GABAB1-/-(orexin) and wild-type littermate mice were 
double-stained with anti-orexin and anti-GABAB1 receptor serum.  Left: orexin-like immunoreactive 
neurons in LHA; middle: GABAB1 receptor-like immunoreactive neurons; right: merged image.  
Lower panels are high-power views of the areas surrounded by the white rectangles in the 
corresponding upper panels.  
 
Figure 2. Lack of Functional GABAB Receptors in Orexin Neurons of GABAB1-/-(orexin) Mice.  (a) 
Effects of GABA (0.6 mM), muscimol (30 μM), baclofen (100 μM), and 5-HT (10 μM) in orexin 
neurons in control mice during current-clamp recording (n=4-8).  Drugs were applied during the 
periods indicated by bars.  (b) Effects of GABA (0.6 mM), muscimol (30 μM), baclofen (100 μM), and 
5-HT (10 μM) in orexin neurons from GABAB1-/-(orexin) mice (n=4-12).  
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
07
.1
19
5.
1 
: P
os
te
d 
29
 S
ep
 2
00
7
Matsuki et al., page 35 
Figure 3. Alteration of Spontaneous Synaptic Input to Orexin Neurons of GABAB1-/-(orexin) Mice.  
(a) sIPSC recordings from brain slices of littermate (control) and GABAB1-/-(orexin) mice.  Basal (upper), 
baclofen (100 μM) application (middle), and after drug washout (lower).  IPSCs were recorded in the 
presence of AP-5 (50 μM) and CNQX (20 μM).  (b) Effects of baclofen on sIPSC frequencies in 
control (n=13) and GABAB1-/-(orexin) (n=9) mice recorded for at least 3 minutes.  (c) In current-clamp 
recording mode, the GABAA receptor antagonist BIC (25 μM) was applied to orexin neurons of 
control (upper, n=4) and GABAB1-/-(orexin) (lower, n=4) mice.  (d) Basal (control, n = 4, cKO, n = 6) and 
mean effect of pre-incubation with OX1R antagonist, SB334867 (5 μM; control n = 9, cKO, n = 7), on 
sIPSC frequency in GABAB1-/-(orexin) (cKO) mice.   Data shown are mean ± SE. *, P < 0.05.  Data were 
analyzed by one way ANOVA or Student’s t test.   (e) Membrane potential of orexin neurons in control 
(n=25) vs. GABAB1-/-(orexin) mice (n=12) in response to a series of 100 msec current steps (in 20 pA 
increments, -200 to 80 pA) from resting potential (-60mV).  Data shown are mean±SE. *, P < 0.05.  
Data were analyzed by one way ANOVA or Student’s t test. 
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Figure 4. Action of GABAA Agonist and Glutamate on Orexin Neurons of GABAB1-/-(orexin) Mice.  
(a) In voltage clamp mode with Vm held at -60 mV, muscimol (10 μM) induced an outward current in 
orexin neurons of control (upper) and GABAB1-/-(orexin) (lower) mice.  The effect of muscimol was 
smaller in GABAB1-/-(orexin) mice.  (b) Dose effects of muscimol on orexin neurons of control (n=6-10) 
vs GABAB1-/-(orexin) mice (n=9-12).  (c) In voltage clamp mode with with Vm held at -60 mV, glutamate 
(100 μM) induced an inward current in orexin neurons of control (upper) and GABAB1-/-(orexin) (lower) 
mice.  The effect of glutamate was smaller in GABAB1-/-(orexin) mice.  (d) Dose effects of glutamate on 
orexin neurons of control (n=5-13) vs GABAB1-/-(orexin) mice (n=3-8).  Representative recordings (a and 
c) and summary data are shown as mean±SE (b and d). 
 
Figure 5. Severe Fragmentation of Sleep Stages in GABAB1-/-(orexin) Mice.  Representative 24 hr 
hypnograms for a GABAB1-/-(orexin) mouse (a) and a control littermate (b).  W, wakefulness; NR, 
non-REM sleep; R, REM sleep.  Note the severe sleep/waking fragmentation, reduced wakefulness 
duration, and reduced REM latency in the GABAB1-/-(orexin) mouse relative to control.  Hourly amounts 
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(c) and average episode duration (d) of awake, non-REM, and REM sleep states (mean±SE) 
plotted over 24 hr for control littermate (n=11) and GABAB1-/-(orexin) mice (n=10).  Data for the dark 
and light phases are displayed on light gray and white backgrounds, respectively. *P < 0.05 by 
Student’s t test. 
Figure 6. Proposed Model in GABAB1-/-(orexin) Mice Displaying Sleep/Wakefulness 
Fragmentation.  GABAA input is increased by compensatory mechanisms, resulting in increased 
membrane conductance of orexin neurons in GABAB1-/-(orexin) mice.  Therefore, orexin neurons in 
GABAB1-/-(orexin) mice show decreased responses to both excitatory and inhibitory input.  In vivo, 
responses of orexin neurons in GABAB1-/-(orexin) mice to wake-active excitatory input or sleep-active 
inhibitory input are inappropriate, resulting in severe instability of sleep/wakefulness states. 
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Supplementary information 
Generation of Transgenic Mice in which Orexin Neurons Specifically Express Cre 
Recombinase 
To achieve orexin neuron-specific Cre expression, a transgene was constructed with the 3.2 kb 
fragment of the 5′-upstream region of the human prepro-orexin gene as a promoter 33, which was 
ligated to the Cre recombinase cDNA fused to an IRES-eGFP construct (Supplementary figure 1a).  
Using this transgene, several transgenic mouse lines, orexin/Cre transgenic mice, were established.  
To confirm Cre expression, immunohistochemical staining was carried out using an anti-Cre 
antibody (Nacalai).  Cre-immunoreactivity (ir) was observed in most (~80%) of the orexin-containing 
neurons (Supplementary figure 1b).  Expression of eGFP could not be detected by 
immunohistochemical or direct GFP fluorescence analysis, suggesting that the IRES-eGFP system 
was non-functional in orexin neurons.  To examine if functional Cre protein is expressed in orexin 
neurons, orexin-Cre mice were crossed with 129-Gt(ROSA)26Sor(EGFP)/J reporter mice38.  This 
confirmed that Cre activity expressed as eGFP-fluorescence was restricted to orexin neurons in the 
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LHA (Supplementary figure 1c).  Similar results were obtained using ROSA-LacZ reporter mice and 
LacZ staining (data not shown).  Extensive examination throughout the brain failed to identify ectopic 
GFP expression other than that in orexin neurons (data not shown).  These observations suggest 
that functional Cre recombinase is exclusively expressed in orexin neurons in orexin/Cre transgenic 
mice.  
Legend for Supplementary figure 1 Transgenic Mice Specifically Expressing Cre 
Recombinase Only in Orexin Neurons.  (a) Structure of the orexin/Cre (IRES-eGFP) transgene, 
consisting of human prepro-orexin promoter, Cre recombinase (Cre) cDNA, IRES-eGFP cDNA, and 
murine protamine-1 gene fragment (mPrm1 polyA).  (b) Specific expression of Cre recombinase by 
orexin-containing neurons in the lateral hypothalamic area (LHA) of orexin/Cre transgenic mice is 
shown by immunofluorescence.  Left, Cre recombinase-like immunoreactivity (Alexa 594, red); 
middle, orexin-like immunoreactivity (Alexa 488, green); right, merged images.  (c) Expression of Cre 
recombinase was monitored by crossing ROSA-eGFP reporter mice.  Left, orexin-like 
immunoreactivity (red); middle, eGFP fluorescence (green); right, merged images.   
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Table 1. Vigilance State Parameters Recorded from GABAB1-/-(orexin) and Control Mice 
  REM  Non-REM  Awake  
Light period  GABAB1-/-(orexin) Control GABAB1-/-(orexin) Control GABAB1-/-(orexin) Control 
(8:00~20:00)  (n=10) (n=11) (n=10) (n=11) (n=10) (n=11) 
Total time 
(min) 
 61.8±3.7 54.6±5.1 402.2±11.6 384.0±16.2 254.1±11.7 280.1±18.5
Duration (sec)  67.3±3.5 78.8±3.2 240.6±24.0** 369.4±27.0 208.0±22.5** 498.2±71.5
Episode 
counts 
 57.0±5.1* 42.1±3.9 108.5±11.8** 65.5±3.6 79.9±7.9** 40.0±4.9 
REM latency 
(sec) 
 295.0±30.5* 410.3±24.8     
Inter-REM 
interval (sec) 
 759.6±79.9 1060.1±103.8     
        
  REM  Non-REM  Awake  
Dark period  GABAB1-/-(orexin) Control GABAB1-/-(orexin) Control GABAB1-/-(orexin) Control 
(20:00~8:00)  (n=10) (n=11) (n=10) (n=11) (n=10) (n=11) 
Total time 
(min) 
 36.7±2.7 32.0±3.0 282.4±12.7 286.9±15.3 400.2±15.0 405.4±20.2
Duration (sec)  69.1±3.2** 84.2±3.2 231.6±22.2** 392.4±40.4 387.1±65.7* 883.7±127.4
Episode 
counts 
 32.9±3.3* 23.5±2.5 82.8±11.8** 46.7±3.6 68.5±12.0** 32.4±3.9 
REM latency 
(sec) 
 285.6±28.3* 503.2±53.6     
Inter-REM 
interval (sec) 
 1356.9±204.2 2091±417.5     
Total time spent in each state (min, mean±SEM), episode duration (sec±SEM), REM latency, and 
interval between successive REM sleep episodes (min, mean±SEM) over 24 hr are itemized 
separately for the light and dark periods.  Significant differences (*P<0.05,**P<0.01; one-way 
ANOVA and post hoc Scheffé’s F test) between GABAB1-/-(orexin) and control (GABAB1flox/flox, orexin/Cre 
negative) mice are indicated with asterisks. 
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